Na+ Channel mRNA Regulation in Heart Failure
NCT03313882 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48
Last updated 2022-03-02
Summary
Human heart failure (HF) has been associated with reduced cardiac sodium channel current and other electrical remodeling. Recently, the investigators have shown that downregulation of cardiac Na+ channels (SCN5A) can contribute to arrhythmic risk and that upregulation can mitigate that risk. Furthermore, the investigators have shown that the reduction in cardiac SCN5A mRNA abundance is reflected in circulating white blood cells (WBCs), which also express SCN5A, and that a reduction in SCN5A is highly predictive of appropriate implanted cardiac defibrillator (ICD) therapy. These data suggest that SCN5A regulation contributes to arrhythmic risk in HF. Other electrical remodeling events thought to contribute to arrhythmic risk include reductions in K+ currents, including Ito, IK1 and IKs are responsible. These current reductions have been linked to reduced transcription, translation and expression of the corresponding channel subunits, such as Kv4.3, Kir2.1, KvLQT1, and accessory proteins including minK and K+ channel interacting protein 2. That all these ion channels are downregulated may suggest a common mechanism to reduce ion channel expression. In this application, the investigators intend to explore an entirely novel mechanism by which SCN5A and other ion channel mRNA abundances are reduced in HF.
Conditions
Interventions
- OTHER
-
no intervention is involved
Sponsors & Collaborators
- lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-08-31
- Primary Completion
- 2016-04-30
- Completion
- 2021-08-01
More Related Trials
-
Liberal Use of Sodium in Ambulatory Heart Failure
NCT04226755 ·Status: COMPLETED ·Phase: NA
-
Natriuretic Peptides as a Prognostic and Risk Stratification Tool in Assessment of Valvular Heart Disease
NCT05439369 ·Status: UNKNOWN
-
Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)
NCT00729222 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
NCT00391846 ·Status: COMPLETED ·Phase: PHASE4
-
SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.
NCT03366181 ·Status: COMPLETED
-
Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine
NCT01373619 ·Status: COMPLETED ·Phase: PHASE4
-
Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
NCT04575428 ·Status: COMPLETED ·Phase: PHASE2
-
NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study
NCT04125966 ·Status: UNKNOWN
-
Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT04628325 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
NCT00288730 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
NCT05168787 ·Status: COMPLETED
-
Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure
NCT03945058 ·Status: TERMINATED ·Phase: NA
-
The Re-Prosper HF Study
NCT04551222 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Acetazolamide in Patients With Acute Heart Failure
NCT03720288 ·Status: UNKNOWN ·Phase: PHASE3
-
Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
NCT02262078 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
NCT02887183 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Urocortins in Patients With Heart Failure
NCT01599728 ·Status: COMPLETED ·Phase: NA
-
STARBRITE: A Randomized Pilot Trial of BNP-Guided Therapy in Patients With Advanced Heart Failure
NCT00484770 ·Status: COMPLETED ·Phase: PHASE2
-
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients
NCT04128878 ·Status: COMPLETED
-
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
NCT03387163 ·Status: COMPLETED
-
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
NCT06137430 ·Status: NOT_YET_RECRUITING
-
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
NCT04217135 ·Status: UNKNOWN ·Phase: PHASE4
-
Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
NCT04397302 ·Status: COMPLETED
-
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects
NCT03565328 ·Status: TERMINATED ·Phase: PHASE2